Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MMRGlobal receives cancer-fighting anti-CD20 monoclonal antibodies patent in Korea
This is the fourth country to issue this patent as a result of the Expedited Patent Allowance Program which follows the issuance of US patents to MMR for
This is the fourth country to issue this patent as a result of the Expedited Patent Allowance Program which follows the issuance of US patents to MMR for
Under the agreement, the investors will purchase an aggregate of 4 million shares of common stock at a purchase price of $5.00 per share. The net proceeds of
Eli Lilly vice president and general patent counsel Doug Norman said: "Lilly respects the intellectual property of others and does not believe the application for approval of its
The lawsuit covers some or all of US patent Nos. 5,061,703; 8,039,009; 8,168,209; 8,173,708; 8,283,379; 8,329,752; 8,362,085; and 8,598,233. Forest licenses the ‘703 patent, which expires in April
After the consolidation, the new division will be called the R&D division. The purposes of the reorganization are to advance Kyowa Hakko Kirin’s ‘category-based strategy’ and enhance the
As part of the partnership, Boehringer Ingelheim and Duke Clinical Research Institute will initiate a prospective, multi-center IPF registry in the US, as well as establish a biomarker
By capitalizing on CreaGen’s chemistry expertise and state-of-the-art laboratory facility, Empiriko is validating methodologies for its transformative Biomimiks technology. Now pharmaceutical customers, for the first time, can use
XBiotech will soon launch its Phase III registration study in Europe to evaluate Xilonix in patients with treatment-resistant colorectal cancer. Cancer treatment centers in at least 6 countries
iBio obtained an exclusive license to patents and related intellectual property for this novel therapy, and then entered a collaboration agreement with the Medical University of South Carolina
The NDA submission is based on a series of laboratory and clinical studies conducted by OptiNose in the US and Europe, including comparative bioavailability and phase II and